stockrow
Friday 6 November 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
30.70
0.56
+1.86%
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) EBITDA
Vera Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$320.1M, compared with −$175.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$417.0M. Over the past ten years it has ranged from −$320.1M (fiscal 2025) to −$11.5M (fiscal 2019) — the current reading is the lowest in ten years. EBITDA has fallen for 4 consecutive fiscal years. Vera Therapeutics, Inc. ranks 569th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$320.1M | — |
| FY2024 | −$175.2M | — |
| FY2023 | −$106.1M | — |
| FY2022 | −$91.7M | — |
| FY2021 | −$34.2M | — |
| FY2020 | −$52.0M | — |
| FY2019 | −$11.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$112.8M | — |
| Mar 2026 | −$125.2M | — |
| Dec 2025 | −$94.5M | — |
| Sep 2025 | −$84.4M | — |
| 22 more quarters | Free account |
Against its own ten years
Low −$320.1M
High −$11.5M
Ten-year median
−$91.7M
Current reading's percentile
14
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| VCEL Vericel Corporation compare | $31.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| IMNM Immunome, Inc. compare | −$268.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$416.8M |
| VERA Vera Therapeutics, Inc. | −$417.0M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item